Margolin A, Avants S K, Kosten T R
Yale University School of Medicine, Department of Psychiatry, New Haven, Connecticut 06519, USA.
Am J Drug Alcohol Abuse. 1995 Nov;21(4):469-81. doi: 10.3109/00952999509002711.
We conducted a double-blind, randomized clinical trial of mazindol (n = 37) for the prevention of relapse to cocaine abuse in methadone-maintained patients who were in the "action" stage of change, i.e., had a history of cocaine dependence but who had been abstinent for at least 2 weeks prior to entry into the study. Eight-one percent of subjects completed the 12-week course of treatment. Overall, cocaine use during the study was comparatively low-17% of the urine screens submitted were positive for cocaine metabolite. Differences between the mazindol and placebo groups of rates of relapse, number of days to relapse, and cocaine use did not reach statistical significance, but were in the direction of a treatment effect. Results suggest that stage of abstinence initiation may be a potentially useful category to employ as an independent variable in future pharmacotherapy trials for the treatment of cocaine addiction in this patient population.
我们对37名处于“行动”改变阶段的美沙酮维持治疗患者进行了一项关于马吲哚预防可卡因滥用复发的双盲随机临床试验，即这些患者有可卡因依赖史，但在进入研究前已戒断至少2周。81%的受试者完成了12周的治疗疗程。总体而言，研究期间可卡因使用相对较少——提交的尿液筛查中有17%可卡因代谢物呈阳性。马吲哚组和安慰剂组在复发率、复发天数和可卡因使用方面的差异未达到统计学显著性，但有治疗效果的趋势。结果表明，禁欲起始阶段可能是未来在该患者群体中进行可卡因成瘾药物治疗试验时作为自变量使用的一个潜在有用类别。
